

CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Anne Arundel Health System, Inc. and Subsidiaries Years Ended June 30, 2013 and 2012 With Report of Independent Auditors

Ernst & Young LLP



Consolidated Financial Statements and Supplementary Information

Years Ended June 30, 2013 and 2012

Contents

Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	
Notes to Consolidated Financial Statements	
Supplementary Information (2013)	
supplementary information (2013)	
Supplementary Consolidating Balance Sheet	46
Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses	48
Anne Arundel Medical Center, Inc. and Subsidiaries:	
Supplementary Consolidating Balance Sheet	49
Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses	
Supplementary Description of Consolidating and Eliminating Entries	



Ernst & Young LLP 621 East Pratt Street Baltimore, MD 21202

Tel: + 1 410 539 7040 Fax: + 1 410 783 3832 www.ey.com

Report of Independent Auditors

Board of Trustees of Anne Arundel Health System, Inc.

We have audited the accompanying consolidated financial statements of Anne Arundel Health System, Inc. (a Maryland not-for-profit corporation) and subsidiaries, which comprise the consolidated balance sheets as of June 30, 2013 and 2012, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We did not audit the financial statements of Cottage Insurance Company, Ltd., a wholly-owned subsidiary, which statements reflect total assets of \$35,532,000 and \$35,909,000 as of June 30, 2013 and 2012, respectively, and net loss after elimination of intercompany revenues of \$1,158,000 and \$1,652,000, respectively, for the years then ended. Those statements were audited by other auditors whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for Cottage Insurance Company, Ltd., is based solely on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not



for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, based on our audits and the report of other auditors, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Anne Arundel Health System, Inc. and subsidiaries as of June 30, 2013 and 2012, and the consolidated results of their operations, changes in their net assets and their cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary consolidating information is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

October 18, 2013

1303-1037905

Ernst + Young LLP

Consolidated Balance Sheets

	June 30)
		2013		2012
Assets				
Current assets:				
Cash and cash equivalents	\$	42,228,000	\$	21,890,000
Short-term investments		2,335,000		2,845,000
Current portion of assets whose use is limited		17,556,000		9,621,000
Patient receivables, less allowance for uncollectible				
accounts of \$16,351,000 and \$15,264,000,				
respectively		77,812,000		60,781,000
Current portion of pledges receivable, net		5,480,000		4,706,000
Inventories, at lower of cost or market		8,316,000		8,506,000
Prepaid expenses and other current assets		9,831,000		10,388,000
Total current assets		163,558,000		118,737,000
Property and equipment		789,480,000		769,409,000
Less accumulated depreciation and amortization		(294,580,000)		(260,041,000)
Net property and equipment		494,900,000		509,368,000
Other assets:				
Investments		224,037,000		203,618,000
Investments in joint ventures		8,215,000		5,418,000
Pledges receivable, net of current portion and net				
of allowance for uncollectible pledges of				
\$724,000 and \$745,000, respectively		7,672,000		9,936,000
Assets whose use is limited		59,861,000		71,850,000
Deferred debt issue costs, net of accumulated				
amortization of \$1,040,000 and \$2,348,000,				
respectively		6,428,000		7,435,000
Restricted collateral for interest rate swap contracts		49,775,000		78,505,000
Other assets		11,749,000	_	11,883,000
Total assets	\$ 1	<u>1,026,195,000</u>	\$	1,016,750,000

3 1303-1037905

	June 30			
	2013		2012	
Liabilities and net assets				
Current liabilities:				
Accounts payable	\$ 22,251,0	00 \$	24,814,000	
Accrued salaries, wages, and benefits	30,528,0	00	29,584,000	
Other accrued expenses	22,536,0	00	21,933,000	
Current portion of long-term debt and capital				
lease obligations	8,232,0	00	9,192,000	
Advances from third-party payors	21,453,0	00	26,357,000	
Total current liabilities	105,000,0	00	111,880,000	
Long-term debt and capital lease obligations,				
less current portion and unamortized original				
issue discount	412,514,0	00	418,574,000	
Interest rate swap contracts	53,002,0	00	82,797,000	
Accrued pension liability	30,604,0	00	35,459,000	
Other long-term liabilities	21,236,0	00	19,172,000	
Total liabilities	622,356,0	00	667,882,000	
Net assets:				
Unrestricted	372,543,0	00	318,413,000	
Temporarily restricted	19,867,0	00	18,893,000	
Permanently restricted	11,429,0	00	11,562,000	
Total net assets	403,839,0	00	348,868,000	
			_	
Total liabilities and net assets	\$ 1,026,195,0	00 \$	1,016,750,000	

1303-1037905

See accompanying notes.

Consolidated Statements of Operations and Changes in Net Assets

	Year Ended June 30		
	2013	2012	
Operating revenue:			
Net patient service revenue	\$ 572,102,000	\$ 550,889,000	
Provision for bad debts	(26,563,000)	(23,554,000)	
Net patient service revenue less provision for bad debts	545,539,000	527,335,000	
Other operating revenue	26,883,000	27,683,000	
Total operating revenue	572,422,000	555,018,000	
Operating expenses:			
Salaries and wages	244,818,000	225,497,000	
Employee benefits	42,067,000	43,823,000	
Medical supplies and drugs	119,323,000	116,079,000	
Purchased services	93,960,000	89,249,000	
Professional fees	16,436,000	15,766,000	
Depreciation and amortization	35,768,000	35,636,000	
Interest	17,226,000	18,226,000	
Total operating expenses	569,598,000	544,276,000	
Operating income	2,824,000	10,742,000	
Other income (loss):	12 550 000	7.045.000	
Investment income, net	13,758,000	7,845,000	
(Loss) income from joint ventures and other, net	(1,341,000)	1,333,000	
Loss on extinguishment of debt	(3,561,000)	_	
Change in unrealized gains (losses) on trading	7 707 000	(4.245.000)	
securities, net	7,797,000	(4,345,000)	
Realized and unrealized gains (losses) on interest	22 522 000	(50 654 000)	
rate swap contracts, net	23,533,000	(50,654,000)	
Total other income (loss), net	40,186,000	(45,821,000)	
Revenues and gains in excess of (less than) expenses	\$ 43,010,000	\$ (35,079,000)	

Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended June 30			Tune 30
		2013		2012
Unrestricted net assets				
Revenues and gains in excess of (less than) expenses	\$	43,010,000	\$	(35,079,000)
Pension liability adjustment		2,993,000		(21,608,000)
Net assets released from restrictions used for purchase		, ,		,
of property and equipment		3,076,000		4,018,000
Transfers and other, net		5,051,000		1,740,000
Increase (decrease) in unrestricted net assets		54,130,000		(50,929,000)
		· · ·		
Temporarily restricted net assets				
Contributions and pledges		7,439,000		6,752,000
Change in net unrealized gains and losses on investments		987,000		(1,291,000)
Temporarily restricted investment income		364,000		375,000
Net assets released from restrictions		(8,310,000)		(7,552,000)
Transfers and other, net		494,000		526,000
Increase (decrease) in temporarily restricted net assets		974,000		(1,190,000)
Permanently restricted net assets				
Contributions for endowment funds		45,000		44,000
Transfers of interest income and other, net		(178,000)		(191,000)
Decrease in permanently restricted net assets		(133,000)		(147,000)
Increase (decrease) in net assets		54,971,000		(52,266,000)
Net assets at beginning of year		348,868,000		401,134,000
Net assets at end of year	\$	403,839,000	\$	348,868,000

See accompanying notes.

Consolidated Statements of Cash Flows

Deceasing activities		Year Ended June 30			
Increase (decrease) in net assets \$4,971,000 \$(52,266,000) Adjustments to reconcile increase (decrease) in net assets to net cash from operating activities: Change in net unrealized gains and losses on investments (8,784,000) 5,636,000 Realized and unrealized (gains) losses on interest rate (23,533,000) 50,654,000 Pension liability adjustment (2,993,000) 21,543,000	Onewating activities		2013		2012
Adjustments to reconcile increase (decrease) in net assets to net cash from operating activities: (8,784,000) 5,636,000 Change in net unrealized gains and losses on investments (8,784,000) 5,636,000 Realized and unrealized (gains) losses on interest rate (23,533,000) 50,654,000 Pension liability adjustment (2979,000) (21,543,000 Equity in earnings of joint ventures and other (297,000) (369,000) Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments - trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net - trading 1,512,000 4,273,000 Net change in operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Inve		4	54 071 000	Φ	(52.266.000)
Cash from operating activities Change in net unrealized gains and losses on investments Realized and unrealized (gains) losses on interest rate swap contracts, net (23,533,000) 50,654,000 Pension liability adjustment (2,993,0000) 21,543,000 Equity in earnings of joint ventures and other (297,000) (369,000) Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 - Depreciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments – trading (11,125,000) (2,030,000) Increase in investments – trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 (4,273,000) Net cash from operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Puresting activities (22,874,000) (23,085,000) (23		Ф	34,971,000	φ	(32,200,000)
Change in net unrealized gains and losses on investments (8,784,000) 5,636,000 Realized and unrealized (gains) losses on interest rate swap contracts, net (23,533,000) 50,654,000 Pension liability adjustment (2,993,000) 21,543,000 Equity in earnings of joint ventures and other (297,000) (369,000) Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 - Depreciation and amortization 35,68,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments – trading (1,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities (22,874,000) (23,085,000) Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets					
Realized and unrealized (gains) losses on interest rate (23,533,000) 50,654,000 swap contracts, net (2,993,000) 21,543,000 Pension liability adjustment (297,000) (369,000) Equity in earnings of joint ventures and other (297,000) (369,000) Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 35,61,000 - Depreciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments - trading (11,125,000) (2,300,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) 6,947,000 Net cash from operating activities 22,874,000 (23,085,000) Investing activities 22,874,000 (23,085,000) Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000			(8.784.000)		5 636 000
swap contracts, net (23,533,000) 50,654,000 Pension liability adjustment (2,993,000) 21,543,000 Equity in earnings of joint ventures and other (297,000) 369,000 Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 35,768,000 35,636,000 Perciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments – trading (11,125,000) 4,273,000 Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 7,615,000 Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investing activities (22,874,000) (23,085,000) Pecrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investing activities (850,000) ((0,704,000)		3,030,000
Pension liability adjustment (2,993,000) 21,543,000 Equity in earnings of joint ventures 763,000 157,000 Distributions received from joint ventures 76,300 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 35,568,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments – trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) 6,947,000 Net cash from operating activities 19,415,000 49,116,000 Investing activities 2,582,000 (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Decrease in assets whose use is limited – other-than-trading 25,744,000 (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (1,919,000) Net			(23 533 000)		50 654 000
Equity in earnings of joint ventures and other (297,000) (369,000) Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 – Depreciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (2030,000) Increase in investments – trading (11,125,000) 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investing activities (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,909,000) Financing and fundraising activities 80,371,000 – <t< td=""><td>•</td><td></td><td>. , , , ,</td><td></td><td></td></t<>	•		. , , , ,		
Distributions received from joint ventures 763,000 157,000 Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 35,636,000 Depreciation and amortization 35,68,000 35,636,000 Restricted investment income (364,000) (20,30,000) Increase in investments – trading (11,125,000) 4,273,000 Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investing activities (3,262,000) (1,919,000) Review of property and equipment (22,874,000) (23,085,000) Investing activities (3,262,000) (1,191,000) Investing activities 880,000 (59,000					
Restricted contributions and pledges, net (7,484,000) (6,796,000) Loss on extinguishment of debt 3,561,000 - Depreciation and amortization 35,768,000 35,660,000 Restricted investments income (364,000) (375,000) Increase in investments – trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net ash from investing activities 880,371,000 59,990,000 Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 20,24,400					
Loss on extinguishment of debt 3,561,000 - Depreciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (2,300,000) Increase in investments - trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net - trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 25,42,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,990,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Repayments of long-term debt and capital lease obligations (8,185,000) (27,476,000) <			,		
Depreciation and amortization 35,768,000 35,636,000 Restricted investment income (364,000) (375,000) Increase in investments – trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities **Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayments of long-term debt and capital lease obligations (8,185,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (5,790,000) <					(0,790,000)
Restricted investment income (364,000) (375,000) Increase in investments – trading (11,125,000) (2,030,000) Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited – other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) 59,090,000 Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Repayments of long-term debt and capital lease obligations (8,185,000) (27,476,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) -					- 25 626 000
Increase in investments – trading C11,125,000 C2,030,000 Decrease in assets whose use is limited, net – trading 1,512,000 4,273,000 Net change in operating assets and liabilities C22,580,000 C6,947,000 Net cash from operating activities 19,415,000 49,116,000					
Decrease in assets whose use is limited, net – trading Net change in operating assets and liabilities 1,512,000 (2,947,000) 4,273,000 (6,947,000) Net cash from operating activities 19,415,000 (23,085,000) 49,116,000 Investing activities 2 Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities 80,371,000 - Poraws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Extinguishment of series 2004A Revenue Bonds (21,300,000) - Payments for de					
Net change in operating assets and liabilities (22,580,000) (6,947,000) Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities 80,371,000 59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Repayments of long-term debt and capital lease obligations (8,185,000) (25,948,000) Repayment of line of credit (5,790,000) 27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (57,470,000) - Restricted contributions received and other 8,974,000 8,578,000	<u> </u>				
Net cash from operating activities 19,415,000 49,116,000 Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities 80,371,000 - Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000					
Investing activities Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net					
Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 <td>Net cash from operating activities</td> <td></td> <td>19,415,000</td> <td></td> <td>49,116,000</td>	Net cash from operating activities		19,415,000		49,116,000
Purchases of property and equipment (22,874,000) (23,085,000) Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 <td>Investing activities</td> <td></td> <td></td> <td></td> <td></td>	Investing activities				
Decrease in assets whose use is limited - other-than-trading 2,542,000 7,615,000 Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities 80,371,000 - Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and	~		(22 874 000)		(23.085.000)
Investment in West County, LLC (3,262,000) (1,919,000) Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000			. , , , ,		
Change in collateralization and payments on interest rate swaps 22,744,000 (41,701,000) Net cash from investing activities (850,000) (59,090,000) Financing and fundraising activities Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000	=				
Financing and fundraising activities (850,000) (59,090,000) Financing and fundraising activities 80,371,000 - Net proceeds from issuance of Series 2012 Revenue Bonds 5,790,000 25,948,000 Repayments on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000					
Financing and fundraising activities 80,371,000 — Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) — Extinguishment of Series 2004A Revenue Bonds (21,300,000) — Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000					
Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000	Net cash from investing activities		(850,000)		(39,090,000)
Net proceeds from issuance of Series 2012 Revenue Bonds 80,371,000 - Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000	Financing and fundraising activities				
Draws on line of credit 5,790,000 25,948,000 Repayments of long-term debt and capital lease obligations (8,185,000) (8,922,000) Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000			80,371,000		_
Repayments of long-term debt and capital lease obligations(8,185,000)(8,922,000)Repayment of line of credit(5,790,000)(27,476,000)Extinguishment of Series 1998 Revenue Bonds(57,470,000)-Extinguishment of Series 2004A Revenue Bonds(21,300,000)-Payments for deferred financing costs(981,000)(17,000)Restricted contributions received and other8,974,0008,578,000Restricted income received364,000375,000Net cash from financing and fundraising activities1,773,000(1,514,000)Net increase (decrease) in cash and cash equivalents20,338,000(11,488,000)Cash and cash equivalents at beginning of year21,890,00033,378,000					25,948,000
Repayment of line of credit (5,790,000) (27,476,000) Extinguishment of Series 1998 Revenue Bonds (57,470,000) - Extinguishment of Series 2004A Revenue Bonds (21,300,000) - Payments for deferred financing costs (981,000) (17,000) Restricted contributions received and other 8,974,000 8,578,000 Restricted income received 364,000 375,000 Net cash from financing and fundraising activities 1,773,000 (1,514,000) Net increase (decrease) in cash and cash equivalents 20,338,000 (11,488,000) Cash and cash equivalents at beginning of year 21,890,000 33,378,000					
Extinguishment of Series 1998 Revenue Bonds Extinguishment of Series 2004A Revenue Bonds Payments for deferred financing costs Restricted contributions received and other Restricted income received Net cash from financing and fundraising activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of year (21,300,000) (17,000) (17,000) 8,578,000 8,578,000 1,773,000 (1,514,000) (1,514,000) 20,338,000 (11,488,000) 33,378,000					
Extinguishment of Series 2004A Revenue Bonds Payments for deferred financing costs Restricted contributions received and other Restricted income received Net cash from financing and fundraising activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of year (21,300,000) - (17,000) 8,578,000 375,000 1,773,000 (1,514,000) 20,338,000 (11,488,000) 33,378,000					_
Payments for deferred financing costs Restricted contributions received and other Restricted income received Net cash from financing and fundraising activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of year (17,000) 8,578,000 375,000 1,773,000 (1,514,000) 20,338,000 (11,488,000) 33,378,000	<u>e</u>				_
Restricted contributions received and other8,974,0008,578,000Restricted income received364,000375,000Net cash from financing and fundraising activities1,773,000(1,514,000)Net increase (decrease) in cash and cash equivalents20,338,000(11,488,000)Cash and cash equivalents at beginning of year21,890,00033,378,000					(17,000)
Restricted income received364,000375,000Net cash from financing and fundraising activities1,773,000(1,514,000)Net increase (decrease) in cash and cash equivalents20,338,000(11,488,000)Cash and cash equivalents at beginning of year21,890,00033,378,000	•				
Net cash from financing and fundraising activities1,773,000(1,514,000)Net increase (decrease) in cash and cash equivalents20,338,000(11,488,000)Cash and cash equivalents at beginning of year21,890,00033,378,000			, ,		
Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of year 20,338,000 (11,488,000) 21,890,000 33,378,000					
Cash and cash equivalents at beginning of year 21,890,000 33,378,000					(1,01.,000)
Cash and cash equivalents at beginning of year 21,890,000 33,378,000	Net increase (decrease) in cash and cash equivalents		20,338,000		(11,488,000)
	•				
	Cash and cash equivalents at end of year	\$	42,228,000	\$	

Consolidated Statements of Cash Flows (continued)

	Year Ended June 30		
	2013	2012	
Changes in operating assets and liabilities			
(Increase) decrease in operating assets:			
Patient receivables, net	\$ (17,031,000) \$	668,000	
Inventories	190,000	(468,000)	
Prepaid expenses and other	1,200,000	(2,643,000)	
Other assets	(1,221,000)	(5,112,000)	
	(16,862,000)	(7,555,000)	
(Decrease) increase in operating liabilities: Accounts payable Accrued salaries, wages, and benefits Other accrued expenses	(2,563,000) 944,000 603,000	(1,233,000) 3,559,000 2,571,000	
Advances from third-party payors	(4,904,000)	4,304,000	
Other long-term liabilities	202,000	(8,593,000)	
	(5,718,000)	608,000	
Net change in operating assets and liabilities	\$ (22,580,000) \$	(6,947,000)	
Supplemental disclosures Cash paid for interest	\$ 17,661,000 \$	17,884,000	

See accompanying notes.

Notes to Consolidated Financial Statements

June 30, 2013

1. Organization and Basis of Presentation

Anne Arundel Health System, Inc. (the Parent or the System) is a Maryland not-for-profit corporation. The Parent has the following wholly owned subsidiaries: Anne Arundel Medical Center, Inc. (the Hospital) and its subsidiaries, Anne Arundel Health Care Services, Inc. (HCS), and Anne Arundel General Treatment Services, Inc. (GTS); Anne Arundel Medical Center Foundation, Inc. (the Foundation); Anne Arundel Health Care Enterprises, Inc. (HCE); Physician Enterprise, LLC (PE) and its subsidiaries, Anne Arundel Physician Group, LLC (AAPG) and Orthopedic Physicians of Annapolis (OPA); Anne Arundel Real Estate Holding Company, Inc. (the Real Estate Company) and its subsidiaries, Pavilion Park, Inc. (PPI), Annapolis Exchange, LLC, and Blue Building, LLC; Anne Arundel Health System Research Institute, Inc. (RI); and Cottage Insurance Company, Ltd. (Cottage). The accompanying consolidated financial statements include the accounts of the Parent and its wholly owned subsidiaries (collectively, the Group). All significant intercompany accounts and transactions have been eliminated in consolidation.

The Real Estate Company and PPI own a 42.84% interest in Kent Island Medical Arts, LLC (KIMA), a limited liability company that owns and operates a medical office building. PPI is the managing member of KIMA and has substantive participation rights in KIMA. The financial statements of KIMA are consolidated in the accompanying consolidated financial statements. The non-controlling interest in KIMA was 57.16% as of June 30, 2013 and 2012. This interest was \$935,000 and \$1,072,000 at June 30, 2013 and 2012, respectively, and is included within unrestricted net assets in the accompanying consolidated balance sheets.

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include cash held in checking and savings accounts, money market accounts, and short-term certificates of deposit with original maturities of 90 days or less. Cash balances, and collateral held by a counterparty, are principally uninsured and are subject to normal credit risks. At June 30, 2013 and 2012, and at various times during the year, the System maintained cash-in-bank balances in excess of the \$250,000 federally insured limits.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Derivative Instruments

On April 25, 2003, the Hospital entered into two interest rate swap derivative contracts to reduce the risk of changing interest rates. On May 10, 2006, the Hospital entered into a forward variable-to-fixed interest rate swap agreement with an effective date of November 1, 2008. This contract was also entered into in an effort to reduce the risk of variable interest rate debt and has a term through July 1, 2048. Under Accounting Standards Codification (ASC) 815, *Derivatives and Hedging*, the Hospital has recognized its derivative instruments as either assets or liabilities in the accompanying consolidated balance sheets at fair value. As these derivative instruments are not designated as hedges, the unrealized gain or loss on these contracts has been recognized in the accompanying consolidated statements of operations and changes in net assets as realized and unrealized gains (losses) on interest rate swap contracts, net. The fair market values of the derivative instruments include a credit valuation adjustment (CVA) as required by ASC 820, *Fair Value Measurements and Disclosures* (ASC 820). When applying the CVA, the valuation of the variable-to-fixed interest rate swap contract was decreased by \$428,000 and \$703,000 as of June 30, 2013 and June 30, 2012, respectively.

In April 2013, the Hospital's variable-to-variable interest rate swap contract and fixed-to-variable interest rate swap contracts matured. The gain recorded at maturity of these contracts was not significant.

A summary of the Hospital's derivative instruments and related activity at June 30, 2013 and 2012, and for the years then ended is as follows:

	2013		
Description of Derivative Instrument	Fair Value Change in Asset Unrealized (Liability) Gain (Loss)		
Variable-to-variable interest rate swap contract Fixed-to-variable interest rate swap contract Variable-to-fixed interest rate swap contract	\$ - \$ 18,000 - (920,000) (53,002,000) 29,777,000		
	\$ (53,002,000) \$ 28,875,000		

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

	2012			
		air Value Asset	Change Unrealiz	zed
Description of Derivative Instrument	(1	Liability)	Gain (Lo	oss)
Variable-to-variable interest rate swap contract	\$	(18,000)	\$ 64,	000
Fixed-to-variable interest rate swap contract		920,000	(923,	(000)
Variable-to-fixed interest rate swap contract	(8	32,779,000)	(44,665,	(000)
	\$ (8	31,877,000)	\$ (45,524,	000)

At June 30, 2013 and 2012, the net termination value (i.e., mark-to-market value) of the derivative instruments totaled \$55,237,000 and \$83,505,000, respectively. The interest rate swap asset amount is included in the other assets line item in the accompanying consolidated balance sheets.

The Hospital may be exposed to credit loss in the event of nonperformance by the other party to the interest rate swap agreements, the risk of which is reflected in the fair value of the instruments under ASC 820. However, the Hospital does not anticipate nonperformance by the counterparty.

During fiscal 2013, the Hospital paid net payments under its interest rate swap program of \$5,342,000. In fiscal 2012, the Hospital paid net payments under its interest rate swap program of \$5,130,000. These amounts are included within realized and unrealized gains (losses) on interest rate swap contracts, net in the accompanying consolidated statements of operations and changes in net assets and investing activities in the accompanying consolidated statements of cash flows.

Under the derivative contracts, the Hospital must transfer collateral for the benefit of the counterparty to the extent that the termination values exceed certain limits. The Hospital's collateral requirement for the benefit of the counterparty was approximately \$49,775,000 and \$78,505,000 at June 30, 2013 and 2012, respectively, for the derivatives. The ongoing mark-to-market values and resulting collateral requirements of the Hospital's interest rate swap contracts are subject to variability based on market factors (primarily changes in interest rates). Collateral requirements under these interest rate swap contracts are excluded from unrestricted cash and investments for purposes of determining the System's compliance with its liquidity covenants under its Maryland Health and Higher Educational Facilities Authority (MHHEFA) revenue

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

bond agreements and its derivative agreements. Collateral amounts are included in noncurrent assets in the accompanying consolidated balance sheets. Due to the timing of settlement with the financial institution, \$1,067,000 of collateral was due to the financial institution and \$424,000 was owed back to the Group at June 30, 2013 and 2012, respectively. These amounts are included in other accrued expenses and prepaid expenses and other current assets in the accompanying consolidated balance sheets as of June 30, 2013 and 2012, respectively, and are reflected within investing activities in the accompanying consolidated statements of cash flows. The collateral requirement as of October 14, 2013, was \$42,851,000.

Assets Whose Use is Limited and Investments

Assets whose use is limited are principally comprised of certain funds established to be held and invested by a trustee. These funds are related to the issuance of the Hospital's Revenue Bonds, investments held at Cottage, and certain permanently restricted endowment assets.

The fair values of publicly traded securities and mutual funds are based on quoted market prices of individual securities or investments or estimated amounts using quoted market prices of similar investments. Hedge fund investments, some of which are structured that the System holds limited partnership interests, are stated at fair value as estimated in an unquoted market. Valuations of these investments, and therefore the System's holdings may be determined by the investment manager or general partner and for "fund of funds" investments are primarily based on financial data supplied by the underlying investee funds. Values may be based on historical cost, appraisals or other estimates that require varying degrees of judgment. Investment income or loss from all unrestricted investments is included in the accompanying consolidated statements of operations and changes in net assets as part of other income.

Investment income or loss on investments of temporarily and permanently restricted assets is added to or deducted from the appropriate restricted fund balance if the income is restricted. The cost of securities sold is based on the specific-identification method.

All investment balances are principally uninsured and subject to normal credit risk. Investments are classified as either current or noncurrent based on maturity dates and availability for current operations. Investments included in noncurrent other assets consist of board-designated investment funds of \$222,335,000 and \$202,035,000 as of June 30, 2013 and 2012, respectively. Based on the System's investment policy, such amounts could be liquidated, at the discretion of the Board, to satisfy short-term requirements.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Substantially all investments, other than borrowed funds required to be expended on capital projects, are classified as trading securities, with unrealized gains and losses included in revenues and gains in excess of (less than) expenses.

Borrowed funds required to be expended on capital projects are classified as other-than-trading and are included in assets whose use is limited.

Patient Receivables and Allowances

The Group's policy is to write off all patient accounts that have been identified as uncollectible. An allowance for doubtful accounts is recorded for accounts not yet written off that are anticipated to become uncollectible in future periods. When determining the allowance, the policy considers the probability of recoverability of accounts based on past experience, taking into account current collection trends. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. The analysis of receivables is performed monthly, and the allowances are adjusted accordingly.

Insurance coverage and credit information are obtained from patients when available. No collateral is obtained for accounts receivable.

Accounts receivable from third-party payors have been adjusted to reflect the difference between charges and the estimated reimbursable amounts.

Inventories

Inventories, which primarily consist of medical supplies and drugs, are carried at the lower of cost or market. Cost is determined using the first-in, first-out method.

Property and Equipment

Property and equipment are stated at cost. Included in computers and software are capitalized labor costs of \$10,267,000 and \$7,922,000 as of June 30, 2013 and 2012, respectively. Depreciation and amortization, including amortization of assets recorded under capital leases, are recorded on the straight-line method over the estimated useful lives of the assets.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The following is a summary of property and equipment, stated at cost:

	Estimated	June 30		
	Useful Lives	2013	2012	
Land	_	\$ 13,151,000	\$ 13,151,000	
Land improvements	20 years	22,016,000	22,003,000	
Buildings and improvements	20-40 years	466,610,000	457,268,000	
Fixed equipment	5-20 years	8,594,000	8,629,000	
Leasehold improvements	5-10 years	48,661,000	43,280,000	
Movable equipment	7-10 years	174,408,000	168,716,000	
Computers and software	3-5 years	54,604,000	50,436,000	
Construction-in-progress	_	1,436,000	5,926,000	
		\$ 5 789,480,000	\$ 769,409,000	

Construction-in-progress consists of direct costs associated with hospital department renovations, certain leasehold improvements, and smaller capital projects. As these projects are completed, the related assets are transferred out of construction-in-progress and into the appropriate asset category and are depreciated over the applicable useful lives.

Investments in Joint Ventures

The System accounts for its investments in joint ventures using the equity method of accounting. During 2011, the Real Estate Company and another party formed West County, LLC, a joint venture that owns and operates a medical office building which opened in December 2012. The Real Estate Company has a 50% interest in this joint venture, with each owner contributing \$7,397,000 and \$4,135,000 as of June 30, 2013 and 2012, respectively.

Deferred Debt Issuance Costs

Administrative, legal, financing, underwriting discount and other miscellaneous expenses that were incurred in connection with debt financings were deferred and are being amortized over the lives of the bond issues using the effective interest method. The amortization expense of deferred debt issue costs was \$376,000 and \$433,000 for the years ended June 30, 2013 and 2012, respectively.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are those whose use by the Group has been limited by donors to a specific time period or purpose. Substantially all temporarily restricted net assets in the accompanying consolidated financial statements are restricted to fund certain Hospital capital additions and operating programs. Permanently restricted net assets have been restricted by donors to be maintained in perpetuity. The income from these funds is expendable to support health care services.

Net Patient Service Revenue

Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. This includes regulatory discounts allowed to Blue Cross, Medicare, Medicaid, and other third-party payors and charity care.

During 2013 and 2012, approximately 36% and 35% of net patient service revenue was received under the Medicare program, 23% and 23% from Blue Cross, 35% and 36% from contracts with other third parties, and 6% and 6% from other sources, respectively.

The following table sets forth the detail of net patient service revenue:

	Year Ended June 30			
		2013	2012	
Gross patient service revenue	\$	743,163,000	\$ 707,863,000	
Revenue deductions:		0.535.000	7.217.000	
Charity care		9,527,000	7,217,000	
Contractual and other allowances		161,533,000	149,757,000	
Net patient service revenue		572,103,000	550,889,000	
Less: Provision for bad debts		26,564,000	23,554,000	
Net patient service revenue less provision for bad debts	\$	545,539,000	\$ 527,335,000	

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Patient accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectibility of accounts receivable, the Hospital analyzes its past history and identifies trends to estimate the appropriate allowance for doubtful accounts and provision for bad debts. For receivables associated with services provided to patients who have third-party coverage, the Hospital analyzes contractually due amounts and provides an allowance for doubtful accounts and a provision for bad debts, if necessary. For receivables associated with self-pay patients (which includes both patients without insurance and patients with deductible and copayment balances due for which third-party coverage exists for part of the bill), the Hospital records a provision for bad debts in the period of service on the basis of its past experience. The difference between the approved rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged off against the allowance for doubtful accounts. The Hospital has not changed its charity care or uninsured discount policies during fiscal years 2013 or 2012.

A substantial amount of the Group's revenues are received from health maintenance organizations and other managed care payors. Managed care payors generally use case management activities to control hospital utilization. These payors also have the ability to select health care providers offering the most cost-effective care. Management does not believe that the Group has undue exposure to any one managed care payor.

The Hospital's revenues may be subject to adjustment as a result of examination by government agencies or contractors, and as a result of differing interpretation of government regulations, medical diagnosis, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until subsequent to the period during which the services were rendered.

The Group employs physicians in several hospital-based specialties (including, but not limited to, obstetrics, intensive care, and hospitalists). Net physician revenue is recognized when the services are provided and recorded at the estimated net realizable amount based on the contractual arrangements with third-party payors and the expected payments from the third-party payors and the patients. The difference between the billed charges and the estimated net realizable amounts are recorded as a reduction in physician revenue when the services are provided. The System recognized net physician revenue of approximately \$63,593,000 and \$52,242,000 for the years ended June 30, 2013 and 2012, respectively. At June 30, 2013 and 2012, approximately \$5,351,000 and \$4,806,000, respectively, of net physician accounts receivable are included in patient receivables in the accompanying consolidated balance sheets.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Charity Care

The Group provides charity care to patients who meet certain criteria established under its charity care guidelines. Because members of the Group do not pursue the collection of amounts determined to qualify as charity care, they are not reported as revenue in the accompanying consolidated statements of operations and changes in net assets. The direct and indirect costs associated with providing this care are \$7,383,000 and \$5,633,000 for the years ended June 30, 2013 and 2012, respectively. These costs are calculated by applying a ratio of operating expenses less bad debt expense over gross patient charges to the charity care provided at established rates. The state of Maryland rate system includes components within the rates to partially compensate hospitals for uncompensated care.

Other Operating Revenue

Other operating revenue is comprised of grant revenue, incentive payments related to the implementation and meaningful use of certified electronic health records, cafeteria revenue, net assets released from restrictions for operating purposes, and other miscellaneous items.

The American Recovery and Reinvestment Act of 2009 provides for Medicare and Medicaid incentive payments beginning in 2011 for eligible hospitals and professionals that implement and achieve meaningful use of certified electronic health record (EHR) technology that demonstrate improved quality and effectiveness of care. Eligibility for annual Medicare incentive payments is dependent on providers demonstrating meaningful use of EHR technology in each period over a four-year period. An additional Medicaid incentive payment is available to providers that adopt, implement or upgrade certified EHR technology. However, in order to receive additional Medicaid incentive payments in subsequent years, providers must demonstrate continued meaningful use of EHR technology.

For Medicare and Medicaid EHR incentive payments, the Hospital utilizes a grant accounting model to recognize these revenues. Under this accounting policy, EHR incentive payments were recognized as revenues when attestation that the EHR meaningful use criteria for the required period of time was demonstrated. The System recognized \$1,518,000 and \$4,911,000 of EHR revenue for the years ended June 30, 2013 and 2012, respectively. These amounts are included in other operating revenue in the accompanying consolidated statements of operations and changes in net assets.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The System's attestation of compliance with the meaningful use criteria is subject to audit by the federal government or its designee. The recognition of the grant income is based on management's best estimate and the amounts recognized are subject to change. Any subsequent changes in the recognition of the grant income will impact the results of operations in the period in which they occur.

Donations and Bequests

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as either temporarily or permanently restricted if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets in the accompanying consolidated statements of operations and changes in net assets. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying consolidated financial statements. Contributions that are unrestricted are reflected as other income in the accompanying consolidated statements of operations and changes in net assets.

Scheduled payments on pledges receivable for the years ending June 30 are as follows:

2014	\$ 5,789,000
2015 - 2018	6,655,000
2019 and thereafter	1,707,000
Less:	
Impact of discounting pledges receivable to net present value	(275,000)
Allowance for uncollectible pledges	(724,000)
Net pledges receivable	\$ 13,152,000

Pledges receivable are discounted using rates between 0.1% and 2.7%.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Revenues and Gains in Excess of (Less than) Expenses

The accompanying consolidated statements of operations and changes in net assets include revenues and gains in excess of (less than) expenses. Changes in unrestricted net assets that are excluded from revenues and gains in excess of (less than) expenses, consistent with industry practice, include contributions received and used for additions of long-lived assets and certain changes in pension liabilities.

Income Tax Status

The Parent, the Hospital, the Foundation, HCS, GTS, PE, and RI have received determination letters from the Internal Revenue Service (IRS) stating that they are exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Real Estate Company has received a determination letter from the IRS stating that it is exempt from federal income taxes under Section 501(c)(2) of the Internal Revenue Code.

HCE and PPI are subject to federal and state income taxes. No provision for income taxes has been recorded for fiscal 2013 and 2012, as these companies and PE do not have taxable income or current tax liabilities. Deferred tax assets (consisting principally of net operating loss carryforwards) are not significant and are not considered to be realizable, given the operations of these entities.

Certain limited liability companies within the consolidated group are not subject to income taxes. Taxable income or loss is passed through to and reportable by the members individually.

Under the Cayman Islands Tax Concessions Law (Revised), the Governor-in-Cabinet issued an undertaking to Cottage on November 29, 2005, exempting it from all local income, profit or capital gains taxes. The undertaking has been issued for a period of 20 years and, at the present time, no such taxes are levied in the Cayman Islands. Accordingly, no provision for taxes is made in these consolidated financial statements.

Under the requirements of ASC 740, *Income Taxes*, tax-exempt organizations could be required to record an obligation as the result of a tax position they have historically taken on various tax exposure items. The Group has determined that it does not have any uncertain tax positions through June 30, 2013.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In July 2011, the Financial Accounting Standards Board (FASB) issued ASU 2011-07, *Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities (a consensus of the FASB Emerging Issues Task Force)*, which provides guidance on the presentation and disclosure of patient service revenue, provisions for bad debts, and the allowance for doubtful accounts for certain health care entities. This guidance changes the presentation of the statement of operations by reclassifying the provision for bad debts associated with patient service revenue from an operating expense to a deduction from patient service revenue (net of contractual allowances and discounts). Additionally, the guidance requires enhanced disclosures about the policies for recognizing revenue and assessing bad debts, as well as qualitative and quantitative information about changes in the allowance for doubtful accounts. The adoption of this guidance resulted in a change in the presentation of the consolidated statement of operations and resulted in additional disclosures related to revenue recognition policies and the allowance for doubtful accounts.

3. Regulatory Environment

Medicare and Medicaid

The Medicare and Medicaid reimbursement programs represent a substantial portion of the Group's revenues. The Group's operations are subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Over the past several years, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violations of these laws and regulations could result in expulsion from

Notes to Consolidated Financial Statements (continued)

3. Regulatory Environment (continued)

government health care programs, together with the imposition of fines and penalties, as well as repayments for patient services previously billed. Compliance with fraud and abuse standards and other government regulations can be subject to future government review and interpretation. Also, future changes in federal and state reimbursement funding mechanisms and related government budgeting constraints could have an adverse effect on the Group.

In 1983, Congress approved a Medicare prospective payment plan for most inpatient services as part of the Social Security Amendment Act of 1983. Hospitals in Maryland are currently exempt from these federal reimbursement regulations under a special waiver. The waiver currently in effect is subject to renewal based upon criteria defined in the federal law. Under these payment arrangements with Medicare, a retroactive adjustment could occur if certain performance standards are not attained by all hospitals on a statewide basis. The impact, if any, of any retroactive adjustment of the Medicare prospective payment system, should hospitals in Maryland become subject to such system, on future operations of the Group, has not been determined.

HSCRC

The Hospital's rate structure for all hospital-based services is subject to review and approval by the Maryland Health Services Cost Review Commission (HSCRC). Under the HSCRC rate-setting system, the Hospital's inpatient charges are subject to an inpatient charge per case target (the Charge Per Case Target). Under the charge per case target methodology, the Hospital monitors its average charge per case compared to HSCRC case mix adjusted targets on a monthly basis. The Charge Per Case (CPC) Target is adjusted annually for inflation, case mix changes, and other factors.

Beginning in fiscal year 2011, the HSCRC adjusted its Charge Per Case policy and removed one-day stay (ODS) cases from the Hospital's case mix and charge per case revenue. ODS cases are now reimbursed on approved HSCRC charges rather than under the case mix adjusted CPC target.

Notes to Consolidated Financial Statements (continued)

3. Regulatory Environment (continued)

Beginning in fiscal year 2012, the Hospital entered into a three-year agreement with the HSCRC to participate in the Admission Readmission Revenue (ARR) program. The ARR arrangement is a voluntary revenue constraint program to incentivize hospitals to coordinate care and reduce unnecessary readmissions. The ARR agreement imposes a case mix adjusted Charge per Episode (CPE) target to inpatient admissions and any subsequent readmission within 30 days of the discharge of the initial admission of the same patient. The CPE target is adjusted annually for inflation, case mix charges, and other factors.

Also beginning in fiscal year 2011, the Commission implemented the Charge Per Visit (CPV) methodology for certain outpatient services. Using fiscal year 2010 as the base period, the actual average 2011 CPV is compared with the base period target. Similar to the CPC target, the CPV target is adjusted annually for inflation, case mix changes and other factors. The outpatient services that are excluded from the CPV methodology are reimbursed on approved HSCRC charges. In March 2012, the HSCRC suspended the outpatient CPV methodology retroactive to July 1, 2011. Until further notice, all outpatient services are reimbursed on approved HSCRC unit rate charge.

Historically, case mix change has been measured by comparing the current fiscal year to the prior fiscal year using rebased weights. In fiscal year 2013, the HSCRC attempted to implement a case mix lag. As such, the FY 2012 base case mix period was compared to the CY 2012 measurement period. In June 2013, the HSCRC reversed its decision and reinstated real time case mix (FY 2013 compared to FY 2012). As a result, the Hospital experienced a greater than expected case mix decline which resulted in an overcharge of approximately \$6.7 million at June 30, 2013. The Hospital was in a net undercharge position of approximately \$4.1 million at June 30, 2012. The Hospital's rates are adjusted in subsequent periods for the over or under charge.

The Hospital's policy is to recognize revenue based on actual charges for services to patients in the year in which the services are performed. The Hospital's revenues may be subject to adjustment as a result of examination by government agencies or contractors, and as a result of differing interpretation of government regulations, medical diagnosis, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until subsequent to the period during which the services were rendered.

Notes to Consolidated Financial Statements (continued)

4. Investments

Investments, consisting of assets whose use is limited and other, are stated at fair value. Borrowed funds that are required to be expended on specified capital projects under MHHEFA revenue bond agreements are classified as "other-than-trading." All other investments and assets whose use is limited are classified as trading securities.

	June 30			
		2013		2012
Assets whose use is limited:				_
Endowment assets:				
Cash and cash equivalents	\$	799,000	\$	802,000
Equity mutual funds		10,302,000		9,064,000
Fixed income mutual funds		3,828,000		4,027,000
		14,929,000		13,893,000
Amounts held by trustee:				_
Cash and cash equivalents		12,617,000		19,090,000
U.S. Government obligations		23,782,000		21,345,000
		36,399,000		40,435,000
Amounts held by Cottage Insurance Company,				
Ltd., a captive insurance subsidiary:				
Cash and cash equivalents		2,730,000		2,748,000
Equity mutual funds		6,896,000		7,933,000
Fixed income mutual funds		15,037,000		16,462,000
Hedge funds		1,426,000		_
		26,089,000		27,143,000
Total assets whose use is limited		77,417,000		81,471,000
Less current portion		17,556,000		9,621,000
	\$	59,861,000	\$	71,850,000

Notes to Consolidated Financial Statements (continued)

4. Investments (continued)

June 30			
2013 2012			
\$ 49,775,000 \$ 78,505,000			
\$ 49,775,000 \$ 78,505,000			
\$ 36,399,000 \$ 40,435,000			
\$ 2,341,000 \$ 2,854,000			
104,246,000 99,702,000			
108,488,000 103,907,000			
11,297,000			
226,372,000 206,463,000			
2,335,000 2,845,000			
\$ 224,037,000 \$ 203,618,000			

Investment income, net of investment fees, and gains (losses) for assets whose use is limited and other investments are comprised of the following:

June 30			
	2013		2012
			_
\$	8,478,000	\$	6,115,000
	5,280,000		1,730,000
\$	13,758,000	\$	7,845,000
\$	7,797,000	\$	(4,345,000)
	\$ \$ \$	\$ 8,478,000 5,280,000 \$ 13,758,000	2013 \$ 8,478,000 \$ 5,280,000 \$ 13,758,000 \$

Notes to Consolidated Financial Statements (continued)

5. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and expands disclosures about fair value measurements. The Group adopted the provisions of ASC 820 for its financial assets and liabilities on July 1, 2008, and for its nonfinancial assets and liabilities on July 1, 2009 (see Note 13).

ASC 820 requires that the fair value of derivative contracts include adjustments related to the credit risks of both parties associated with the derivative transactions. The fair value of the Group's derivative contracts reflected in the accompanying consolidated financial statements include adjustments related to the credit risks of the parties to the transactions.

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: $Level\ 1$ – defined as observable inputs, such as quoted prices in active markets; $Level\ 2$ – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and $Level\ 3$ – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Group believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Notes to Consolidated Financial Statements (continued)

5. Fair Value Measurements (continued)

The following tables present the fair value hierarchy for the Group's financial assets and liabilities measured at fair value on a recurring basis at June 30, 2013 and 2012:

Y 00 0010	m . 1	Quoted Prices in Active Markets for Identical Assets	Significant Other Observable Inputs	Significant Unobservable Inputs
June 30, 2013	Total	Level 1	Level 2	Level 3
Assets: Cash and cash equivalents Trading securities and other assets whose use is limited:	\$ 42,228,000	\$ 32,728,000	\$ 9,500,000	\$ -
Cash and cash equivalents	18,487,000	12,617,000	5,870,000	_
Equity funds	121,444,000	114,548,000	6,896,000	_
Fixed income funds	127,353,000	112,316,000	15,037,000	_
U.S. obligation funds	23,782,000	_	23,782,000	_
Hedge funds	12,723,000		12,723,000	
Total	303,789,000	239,481,000	64,308,000	_
Collateral for interest rate swap: Cash and cash equivalents	49,775,000	49,775,000	_	_
Total assets	\$395,792,000	\$ 321,984,000	\$ 73,808,000	\$ -
Liabilities:				
Derivative instruments	\$ (53,002,000)	\$ -	\$ (53,002,000)	\$ -
Total liabilities	\$ (53,002,000)	\$ -	\$ (53,002,000)	\$ –

Notes to Consolidated Financial Statements (continued)

5. Fair Value Measurements (continued)

		Quoted Prices in Active Markets for Identical Assets	Significant Other Observable Inputs	Significant Unobservable Inputs
June 30, 2012	Total	Level 1	Level 2	Level 3
Assets:				
Cash and cash equivalents	\$ 21,890,000	\$ 10,131,000	\$ 11,759,000	\$ -
Trading securities and other assets whose use is limited:				
Cash and cash equivalents	25,494,000	19,090,000	6,404,000	_
Equity funds	116,699,000	108,766,000	7,933,000	_
Fixed income funds	124,397,000	107,935,000	16,462,000	_
U.S. obligation funds	21,344,000	_	21,344,000	
Total	287,934,000	235,791,000	52,143,000	_
Collateral for interest rate swap:				
Cash and cash equivalents	78,505,000	78,505,000	_	_
Derivative instruments	920,000	_	920,000	
Total assets	\$ 389,249,000	\$ 324,427,000	\$ 64,822,000	\$
Liabilities:				
Derivative instruments	\$ (82,797,000)	\$ -	\$ (82,797,000)	\$
Total liabilities	\$ (82,797,000)	\$ -	\$ (82,797,000)	\$ -

The Group's Level 1 securities primarily consist of U.S. Treasury securities, exchange-traded mutual funds, and cash. The Group determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.

The Group's Level 2 securities primarily consist of U.S. government-sponsored entities bonds and money market funds. The Group determines the estimated fair value for these Level 2 securities using the following methods: quoted prices for similar assets/liabilities in active markets, quoted prices for identical or similar assets in non-active markets (few transactions, limited information, non-current prices, high variability over time), inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.), and inputs that are derived principally from or corroborated by other observable market data. The System's hedge funds are also considered Level 2 investments as the System has the ability to redeem its investment with the investee at net asset value per share (or its equivalent) at the measurement date.

1303-1037905 27

Notes to Consolidated Financial Statements (continued)

5. Fair Value Measurements (continued)

The Group's Level 2 securities also consist of derivative instruments, which are reported using valuation models commonly used for derivatives. Valuation models require a variety of inputs, including contractual terms, market fixed prices, inputs from forward price yield curves, notional quantities, measures of volatility, and correlations of such inputs.

The Group also has pledges receivable, which are measured at fair value on a non-recurring basis and are discounted to net present value upon receipt using an appropriate risk-free discount rate based on the term of the receivable. Since these inputs are not observable, pledges receivable would be considered Level 3 fair value measurements upon their initial recording. Pledges receivable are recorded net of an allowance for uncollectible pledges. The following table provides a reconciliation of the beginning and ending balances of pledges receivable that used significant unobservable inputs:

	Year Ended June 30		
	2013	2012	
Pledges receivable:			
Balance at July 1	\$ 14,642,000	\$ 16,424,000	
New pledges	4,081,000	4,182,000	
Collections on pledges	(5,357,000)	(5,968,000)	
Write-off of pledges	(235,000)	(103,000)	
Changes in reserves	21,000	107,000	
Balance at June 30	\$ 13,152,000	\$ 14,642,000	

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit

Long-term debt consists of the following:

	Interest	Maturity	June 30	
	Rate	Dates	2013	2012
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 2012	2.0 - 5.0%	2013 - 2034	\$ 73,625,000	\$ -
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 2010	4.0 - 5.0%	2011 - 2040	81,220,000	82,830,000
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 2009A	4.0 - 6.75%	2013 - 2040	118,815,000	120,000,000
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 2009B	Variable	2041 - 2044	60,000,000	60,000,000
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 2004A	2.0 - 5.0%	2006 - 2035	_	21,880,000
Maryland Health and Higher				
Educational Facilities Authority				
Revenue Bonds – Series 1998	4.2 - 5.25%	2003 - 2033	_	58,980,000
2008 term loan from a bank	Variable	2018	50,654,000	52,556,000
Kent Island term loan from a bank	Variable	2015	7,833,000	8,173,000
Bank line of credit	Variable	2014	_	_
2008 construction loan from a bank	Variable	2018	26,579,000	27,576,000
			418,726,000	431,995,000
Less current portion of long-term debt			7,432,000	8,122,000
Less unamortized original issue				
(premium) discount			(1,130,000)	6,052,000
Long-term debt			\$ 412,424,000	\$ 417,821,000

These debt instruments are secured by the receipts of the Hospital and substantially all of the property and equipment of the consolidated group.

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit (continued)

Principal payments due under all debt instruments as of June 30, 2013, are as follows:

2014	\$ 7,432,000
2015	8,508,000
2016	8,741,000
2017	15,408,000
2018	9,033,000
Thereafter	369,604,000
	\$ 418,726,000

Series 2012 Revenue Bonds

In October 2012, the Hospital entered into a loan agreement with MHHEFA for the issuance of \$73,625,000 of Series 2012 Revenue Bonds (referred to as the 2012 Bonds). The proceeds of the 2012 Bonds were used to repay the Series 2004A Bonds and the Series 1998 Bonds previously provided by the Authority. The bonds being refinanced were originally obtained to finance a new replacement hospital (1998 Bonds) and to finance major renovations to the Hospital's Cancer Center and land acquisition (2004A Bonds). The 2012 Bonds provide for annual principal payments each July 1, from 2013 through 2034. Interest is payable semi-annually on each July 1 and January 1, beginning July 1, 2010. The 2012 Bonds bear stated interest at rates of 2.00% to 5.00%, and were issued at a premium of \$6,746,000. The effective annual interest rate for the 2012 Bonds for the year ended June 30, 2013 was 2.46%.

The provisions of the 2012 Bonds, together with the 2010 Bonds, 2009 Bonds, 2004 Bonds, and the 1998 Bonds, require the Parent and subsidiaries to comply with certain covenants on an annual basis, including a debt service coverage requirement, a debt to capitalization requirement, and a liquidity requirement.

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit (continued)

Series 2010 Revenue Bonds

In February 2010, the Hospital entered into a loan agreement with MHHEFA for the issuance of \$85,410,000 of Series 2010 Revenue Bonds (referred to as the 2010 Bonds). The proceeds of the 2010 Bonds were used to repay the Series 2004B Bonds and Dedicated Financing previously provided by the Authority and are being used to finance the expansion of the parking garage for the Hospital's acute care pavilion. The 2010 Bonds provide for annual principal payments each July 1, from 2011 through 2040. Interest is payable semi-annually on each July 1 and January 1, beginning July 1, 2010. The 2010 Bonds bear stated interest at rates of 3.00% to 5.00%, and were issued at an original issue discount of \$1,507,000. The effective annual interest rates for the 2010 Bonds for the years ended June 30, 2013 and 2012, were 4.85% and 4.86%, respectively.

Series 2009 Revenue Bonds

In January 2009, the Hospital entered into a loan agreement with MHHEFA for the issuance of \$120,000,000 Series 2009A Revenue Bonds (the 2009A Bonds) and in February 2009, \$60,000,000 Series 2009B Revenue Bonds (the 2009B Bonds) (collectively referred to as the 2009 Bonds). The proceeds of the 2009 Bonds are being used to finance a portion of the costs of construction of an eight-story patient care building, two new parking garages, and certain costs relating to the issuance. The 2009A Bonds provide for annual principal payments each July 1, from 2012 through 2039. Interest is payable semi-annually on each July 1 and January 1, beginning July 1, 2009. The 2009B Bonds provide for annual principal payments each July 1, from 2040 through 2043. Interest is payable semi-annually on each July 1 and January 1, beginning July 1, 2009. The 2009A Bonds bear stated interest at rates of 4.00% to 6.75%. The 2009A Bonds were issued at an original issue discount of \$4,817,000. The effective annual interest rates for the 2009A Bonds for the years ended June 30, 2013 and 2012, were 6.71% and 6.64%, respectively. The 2009B Bonds bear interest at variable rates, as set forth in the loan agreement. The maximum interest rate is 12% for the 2009B Bonds. The effective annual interest rates for the 2009B Bonds for the years ended June 30, 2013 and 2012, were 0.19% and 0.17%, respectively. The principal and interest payments on the Series 2009B Bonds are secured by a letter of credit equal to the original principal of the bonds plus an amount equal to 40 days' interest thereon, calculated at the maximum rate. The current letter of credit expires in May 2016. Under certain circumstances, the Hospital would need to fully redeem the 2009B Bonds upon expiration of the letter of credit, unless a conforming replacement letter of credit was secured prior to such expiration. The Hospital, the Parent, and HCS are members of the obligated group for the 2009 Bonds.

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit (continued)

Series 2004 Revenue Bonds

In February 2004, the Hospital entered into a loan agreement with MHHEFA for the issuance of \$25,570,000 Series 2004A Revenue Bonds (the 2004A Bonds), and \$64,250,000 Series 2004B Revenue Bonds (the 2004B Bonds) (collectively referred to as the 2004 Bonds). The proceeds of the 2004A and 2004B Bonds were used to finance and refinance the costs of acquisition, construction, renovation and equipping of the 2004 Project; to repay certain debt; to fund debt service reserve requirements; and to pay certain other costs relating to the issuance. The 2004 Project included renovations to the Hospital's Cancer Center together with new furnishings and equipment, acquisition of 21 acres of land and acquisition and installation of capital equipment and furnishings. Concurrent with the issuance of the 2004 Bonds, the Parent and HCS became members of the obligated group for the 2004 Bonds and the 1998 Bonds. In February 2010, the 2004B Bonds were extinguished through an advance refunding financed by proceeds from the 2010 Bonds.

In October 2012, the 2004A Bonds were extinguished through the advance refunding financed by proceeds from the 2012 Bonds. The hospital paid a prepayment penalty of approximately \$1,500,000 to extinguish the 2004A Bonds. The remaining unamortized deferred financing costs and premium totaling \$853,000 were written off upon extinguishment of the 2004A Bonds and together with the prepayment penalty are recorded as a loss on extinguishment of debt in the accompanying consolidated statements of operations and changes in net assets for the year ended June 30, 2013.

Series 1998 Revenue Bonds

In August 1998, the Hospital and its subsidiaries entered into a loan agreement with MHHEFA for the issuance of \$69,840,000 of Series 1998 Revenue Bonds (the 1998 Bonds). The proceeds were used to finance the acquisition, construction and equipping of a new replacement hospital, the renovation and equipping of certain existing facilities, the purchase of capital equipment and the payment of certain other costs relating to the issuance.

In October 2012, the 1998 Bonds were extinguished through an advance refunding financed by the proceeds from the 2012 Bonds. The remaining unamortized deferred financing costs and discount totaling \$1,208,000 were written off upon extinguishment of the 1998 Bonds and recorded as a loss on the extinguishment of debt in the accompanying consolidated statements of the operations and changes in net assets for the year ended June 30, 2013.

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit (continued)

The related balances are included in assets whose use is limited and consist of the following:

	June 30				
	2013			2012	
Debt service funds Debt service reserve funds	\$	14,829,000 20,534,000	\$	16,131,000 20,864,000	
Construction fund and capitalized interest fund		1,036,000		3,440,000	
	\$	36,399,000	\$	40,435,000	

Bank Line of Credit and Term Loan

The Hospital maintains a line of credit with a bank providing available credit of \$30,000,000. The agreement with the bank is reviewed for renewal on February 28 of each year. Interest on any borrowings accrues at the One Month London Interbank Offered Rate (LIBOR) plus 1.5%. At June 30, 2013 and 2012, the Group has no balance on the line of credit.

On October 23, 2008, the Real Estate Company secured a term loan in the amount of \$55,000,000 with a bank. The proceeds from the term loan were used to refinance line of credit proceeds and fund certain construction costs related to a medical office building. The loan bears interest at a variable rate, based on the LIBOR Market Index Rate plus 1.25%. The term loan has a final maturity of November 5, 2018. The effective annual interest rates for the years ended June 30, 2013 and 2012, were 1.48% and 1.52%, respectively.

2008 Construction Loan

On October 23, 2008, the Real Estate Company entered into a construction loan in the amount of \$30,000,000 with a bank to fund the construction of a medical office building. The loan was issued under the same loan agreement as the term loan discussed in the immediately preceding paragraph. The debt is secured by the medical office building. Interest only is due during the construction period at a rate equal to the LIBOR Market Index Rate plus 1.25%. The loan converted to a term loan after the completion of the construction in July 2009. The term loan provides for monthly principal and interest payments and has a final maturity of November 5, 2018. The effective annual interest rates for the years ended June 30, 2013 and 2012, were 1.48% and 1.52%, respectively.

Notes to Consolidated Financial Statements (continued)

6. Long-Term Debt and Lines of Credit (continued)

Kent Island Term Loan

In August 2007, KIMA entered into a construction loan agreement with a bank in the amount of \$9,000,000 that would convert to a term loan after the completion of the construction. The proceeds were used to construct a medical office building. The debt is secured by the medical office building. Interest only was due during the construction period at a rate of the 30-day LIBOR rate plus 1.0%. The construction was completed in June 2008. The term loan provides for monthly principal and interest payments and has a final maturity of June 2015. The effective annual interest rates for the years ended June 30, 2013 and 2012, were 1.08% and 1.11%, respectively.

7. Capital Lease Obligations

The Group has entered into capital lease agreements for certain medical equipment and software at a cost of \$7,432,000 as of June 30, 2013 and 2012. Accumulated amortization on these assets was \$5,257,000 and \$4,075,000 as of June 30, 2013 and 2012, respectively. Future payments under these capital lease obligations are as follows:

2014	\$ 825,000
2015	90,000
Total payments	915,000
Less amount deemed to represent interest	(25,000)
	890,000
Less current portion	(800,000)
	\$ 90,000

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan

The Hospital has a qualified noncontributory, defined benefit pension plan (the Plan) that covers substantially all employees. The Group's policy is to fund pension costs as determined by its actuary. Adopted by the Board of Trustees on June 11, 2009, and effective September 1, 2009, the Hospital amended the Plan to freeze future benefit accruals, and participants have not earned any additional benefits under the Plan since that date. However, subsequent to September 1, 2009, participants have continued to vest in benefits they have earned through September 1, 2009. The frozen benefit balance for the participants will only accrue interest credits until the participants' benefit commencement dates. FASB ASC 715, Compensation – Retirement Benefits (ASC 715) requires the Group to recognize the funded status (i.e., the difference between the fair value of plan assets and the projected benefit obligations) of its pension plan on its consolidated balance sheet, with a corresponding adjustment to unrestricted net assets. The pension liability adjustment to unrestricted net assets represents the change in net unrecognized actuarial losses and unrecognized prior service costs which have not yet been recognized as part of revenues and gains in excess of (less than) expenses. These amounts are subsequently recognized as net periodic pension cost pursuant to the Group's historical accounting policy for amortizing such amounts.

During the year ended June 30, 2013, a partial settlement of the Plan's defined benefit obligation was recognized. Since the settlement was more than minor, ASC 715 requires that a pro rata amount of the net loss in accumulated unrestricted net assets is charged to excess of revenues over expenses based on the proportion of the projected benefit obligation settled to the total projected benefit obligation. The settlement has been recognized and measured as of June 30, 2013. As of June 30, 2013, the Group determined that a settlement had occurred and recognized a loss of \$2,963,000 that was recorded within (loss) income from joint ventures and other, net in the consolidated statements of operations and changes in net assets.

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan (continued)

During the year ended June 30, 2013, an error was identified in the calculation of the discount rate which resulted in the understatement of the unfunded liability in the prior year financial statements. The impact to the prior year statements was determined to be immaterial and the correction was recorded in the current year as an actuarial loss. The reconciliation of the beginning and ending balances of the projected benefit obligation and the fair value of plan assets for the years ended June 30, 2013 and 2012, and the accumulated benefit obligation at June 30, 2013 and 2012, is as follows:

	June 30				
	2013	2012			
Accumulated benefit obligation	\$ 112,402,000 \$	5 111,955,000			
Change in projected benefit obligation:					
Projected benefit obligation at beginning of year	\$ 111,955,000	96,341,000			
Service cost	_	_			
Interest cost	4,653,000	5,473,000			
Actuarial loss	3,293,000	14,625,000			
Benefits paid	(984,000)	(4,484,000)			
Settlements paid	(6,515,000)				
Projected benefit obligation at end of year	112,402,000	111,955,000			
Change in plan assets:					
Fair value of plan assets at beginning of year	76,496,000	76,725,000			
Actual return on plan assets	8,336,000	(1,445,000)			
Employer contribution	4,465,000	5,700,000			
Benefits paid	(984,000)	(4,484,000)			
Settlements paid	(6,515,000)				
Fair value of plan assets at end of year	81,798,000	76,496,000			
Net liability recognized	\$ (30,604,000)	(35,459,000)			

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan (continued)

	June 30				
		2013	2012		
Net amounts recognized in the consolidated balance sheets consist of: Accrued pension costs	\$	(30.604.000) \$ (35,459,000)		
1.101.000 P.1.101.0	<u>Ψ</u>	(20,001,000	, + (55, 155, 555)		
Amounts recognized in accumulated unrestricted net assets that have not been recognized in net periodic benefit cost (credit) consist of:					
Net actuarial loss	<u>\$</u>	51,123,000	\$ 54,116,000		

The following table sets forth the weighted-average assumptions used to determine benefit obligations:

	June 30			
	2013	2012		
Discount rate	4.45%	4.25%		
Rate of compensation increase	N/A	N/A		

The following table sets forth the weighted-average assumptions used to determine net periodic benefit cost (credit):

	Year Ended June 30			
	2013	2012		
Discount rate	4.25%	5.80%		
Expected return on plan assets	7.50%	7.75%		
Rate of compensation increase	N/A	N/A		

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan (continued)

Net periodic pension benefit cost (credit) included the following components:

	June 30				
	2013	2012			
Service cost	\$ -	\$ -			
Interest cost	4,653,000	5,473,000			
Expected return on plan assets	(6,063,000)	(6,074,000)			
Amortization of prior service cost	_	_			
Recognized net actuarial loss	1,066,000	583,000			
Loss recognized from partial settlement of					
projected benefit obligation	2,963,000	_			
Net periodic benefit cost (credit)	\$ 2,619,000	\$ (18,000)			

The estimated net loss for the defined benefit pension plans that will be amortized from unrestricted net assets into net periodic benefit credit over the next fiscal year is \$1,138,000.

The Hospital's defined benefit plan invests in a diversified mix of traditional asset classes. Investments in certain types of U.S. equity securities and fixed income securities are made to maximize long-term results while recognizing the need for adequate liquidity to meet ongoing benefit and administrative obligations. Risk tolerance of unexpected investment and actuarial outcomes is continually evaluated by understanding the pension plan's liability characteristics. Equity investments are used primarily to increase overall plan returns. Debt securities provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.

The Hospital's target asset allocation percentages as of June 30, 2013, were as follows: 19% large cap domestic stocks, 8% small cap domestic stocks, 22% international stocks, 6% emerging market stocks, 5% exchange-traded notes, and 40% U.S. investment grade bonds.

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan (continued)

The following tables present the fair value hierarchy of assets of the defined benefit pension plan at June 30, 2013 and 2012, respectively:

	Total	Quoted Prices in Active Significant Markets for Other Identical Observable Assets Inputs Level 1 Level 2			Significant nobservable Inputs Level 3	
June 30, 2013	 20002					
Assets:						
Cash and cash equivalents	\$ 850,000	\$	_	\$ 850,000	\$	_
Mutual funds:						
Equity	24,254,000		24,254,000	_		_
Government bonds	30,007,000		30,007,000	_		_
International equity	22,163,000		22,163,000	_		_
Exchange traded notes	4,524,000		4,524,000	_		_
Total	\$ 81,798,000	\$	80,948,000	\$ 850,000	\$	_
			uoted Prices in Active Markets for Identical Assets	Significant Other Observable Inputs		Significant nobservable Inputs
	Total		in Active Markets for Identical	Other Observable		nobservable
June 30, 2012 Assets: Cash and cash equivalents	\$ Total 1,017,000		in Active Markets for Identical Assets	Other Observable Inputs	Uı	nobservable Inputs
Assets:	\$		in Active Markets for Identical Assets	 Other Observable Inputs Level 2	Uı	nobservable Inputs
Assets: Cash and cash equivalents	\$		in Active Markets for Identical Assets	 Other Observable Inputs Level 2	Uı	nobservable Inputs
Assets: Cash and cash equivalents Mutual funds:	\$ 1,017,000		in Active Markets for Identical Assets Level 1	 Other Observable Inputs Level 2	Uı	nobservable Inputs
Assets: Cash and cash equivalents Mutual funds: Equity	\$ 1,017,000 25,066,000		in Active Markets for Identical Assets Level 1	 Other Observable Inputs Level 2	Uı	nobservable Inputs
Assets: Cash and cash equivalents Mutual funds: Equity Corporate bonds	\$ 1,017,000 25,066,000 3,958,000		in Active Markets for Identical Assets Level 1	 Other Observable Inputs Level 2	Uı	nobservable Inputs

Notes to Consolidated Financial Statements (continued)

8. Pension Plan and Thrift Plan (continued)

Level 1 securities primarily consist of exchange-traded mutual funds. Level 2 securities primarily consist of money market funds. Methods consistent with those discussed in Note 5 are used to estimate the fair values of these securities.

The overall rate of expected return on assets assumption was based on historical returns, with adjustments made to reflect expectations of future returns. The extent to which the future expectations were recognized considered the target rates of return for the future, which have historically not changed.

The Hospital does not have any regulatory contribution requirements; however, the Hospital currently intends to make voluntary contributions to the defined benefit pension plan of \$9,526,500 in fiscal 2014.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

2014	\$ 6,530,000
2015	6,884,000
2016	6,567,000
2017	6,056,000
2018	6,395,000
2018–2023	37,652,000

In addition to the noncontributory, defined benefit pension plan, the Hospital also offers an employee thrift plan. Participation in the plan is voluntary. Substantially all full-time employees of the Hospital are eligible to participate. Employees may elect to contribute a minimum of 1% of compensation, and a maximum amount as determined by Sections 403(b) and 415 of the Internal Revenue Code. Any employee making contributions to the plan is entitled to a Hospital contribution that will match the employee contribution at the rate of 50% to 75%, depending on the number of years of service, up to a maximum of 4% of qualified compensation. Matching contributions under this thrift plan were \$2,681,000 and \$2,556,000 in fiscal years 2013 and 2012, respectively.

Notes to Consolidated Financial Statements (continued)

9. Concentrations of Credit Risk

Certain members of the Group grant credit without collateral to their patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors was as follows:

	June 30			
	2013	2012		
Medicare	34%	27%		
Medicaid	3	5		
Blue Cross	20	23		
Commercial, HMO, PPO and other	27	30		
Patients	16	15		
	100%	100%		

10. Malpractice Insurance Costs and Self-Insured Professional Liability

Until August 1, 1998, the Group maintained insurance coverage for general and professional liability claims on a claims-made basis. The professional liability coverage included a per-case deductible of \$250,000, up to a maximum out-of-pocket amount of \$750,000 annually. Effective August 1, 1998, the Group changed its professional liability coverage to a full coverage claims-made policy with no annual deductibles. This policy included tail coverage for claims incurred prior to August 1, 1998, but reported subsequently. Effective August 1, 2002, the Group changed its professional liability coverage back to a claims-made policy with a per-case deductible of \$250,000, up to a maximum out-of-pocket amount of \$750,000 annually. Also, the Group did not purchase tail coverage for claims incurred prior to August 1, 2002 not yet reported.

Effective March 1, 2004, the Group changed its professional liability coverage to a self-insurance trust with annual exposure limits of \$2,000,000 per claim and \$11,000,000 in aggregate. The Group carried an excess liability insurance policy for claims above these limits.

Notes to Consolidated Financial Statements (continued)

10. Malpractice Insurance Costs and Self-Insured Professional Liability (continued)

Effective July 1, 2005, Cottage was formed as a captive insurer to provide professional liability insurance for the Group. Cottage is a wholly owned subsidiary of the System, which was formed in the Cayman Islands. The primary layer of professional and general liability insurance coverage is self-insured through Cottage and the secondary layer is fully reinsured through a commercial carrier.

For the period July 1, 2005 to June 30, 2009, Cottage issued claims-made policies covering hospital professional liability (including employed physicians) and on an occurrence basis, comprehensive general liability risks of the Parent and certain affiliates. Policy limits were \$2,000,000 per claim with a \$9,000,000 policy aggregate. Effective July 1, 2005, Cottage assumed existing liabilities from the System's self-insured trust discussed above on a claims-made basis. Effective July 1, 2009, Cottage issued a claims-made policy providing \$2,000,000 per claim hospital professional liability coverage and \$1,000,000 per claim comprehensive general liability coverage, subject to a consolidated annual aggregate limit of \$10,000,000.

For the period July 1, 2005 to June 30, 2008, Cottage also issued an excess umbrella coverage policy (covering hospital professional liability) with limits of \$20,000,000 per claim and in the policy aggregate. For claims reported on and subsequent to July 1, 2008, the coverage limit provided is \$30,000,000 per claim and in the policy aggregate. These excess limits are in excess of the primary policy, and the umbrella policies are 100% reinsured with third-party commercial reinsurers.

The provision for estimated professional liability claims, general liability claims, and workers' compensation claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported. As of June 30, 2013 and 2012, the balance for outstanding claims reserves recorded at Cottage is \$21,898,000 and \$20,432,000, respectively. The remaining tail liability for claims incurred but not reported is \$6,365,000 and \$6,529,000 as of June 30, 2013 and 2012, with \$5,132,000 of the 2013 liability, and \$5,326,000 of the 2012 liability recorded at the Hospital. The remainder of the liability is recorded at PE. The Group has employed an independent actuary to estimate the ultimate settlement of such claims. In management's opinion, the amounts recorded provide an adequate reserve for loss contingencies. However, changes in circumstances affecting professional liability claims could cause these estimates to change by material amounts in the short term.

Notes to Consolidated Financial Statements (continued)

11. Commitments and Contingencies

Operating Leases

Various members of the Group have operating leases for storage space, equipment, and offices. During 2013 and 2012, rent expense on these leases was approximately \$9,695,000 and \$7,077,000, respectively. Future minimum annual rental payments under noncancelable operating leases, which expire through 2019, are as follows:

2014	\$ 7,920,000
2015	5,753,000
2016	4,687,000
2017	2,758,000
2018	2,445,000
Thereafter	3,821,000
	\$ 27,384,000

Contracted Construction Commitments

Members of the Group have future construction commitments with outside contractors for various projects totaling \$616,000 and \$2,324,000 as of June 30, 2013 and 2012, respectively.

Contingencies

Members of the Group have been named as defendants in various legal proceedings arising from the performance of their normal activities. In the opinion of management, after consultation with legal counsel and after consideration of applicable insurance, the amount of the Group's ultimate liability under all current legal proceedings will not have a material adverse effect on its consolidated financial position or results of operations.

The Group's revenues may be subject to adjustment as a result of examination by government agencies or contractors based upon differing interpretation of government regulations, medical diagnosis, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until subsequent to the period during which the services were rendered. Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. We have established

Notes to Consolidated Financial Statements (continued)

11. Commitments and Contingencies (continued)

protocols to respond to RAC requests and payment denials. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and we intend to pursue the reversal of adverse determinations where appropriate. In addition to overpayments that are not reversed on appeal, we will incur additional costs to respond to requests for records and pursue the reversal of payment denials. As of June 30, 2013 and 2012, the Group has recorded an estimated reserve regarding the Medicare overpayments. In the opinion of the Group's management, the ultimate settlement of this matter will not have a material adverse effect on the financial position of the Group.

12. Functional Expenses

Members of the Group provide general health care services to residents within their service area. Expenses related to providing these services are as follows:

	2013 2012
Health care services General and administrative	\$ 482,612,000 \$ 455,166,000 86,986,000 89,110,000
	\$ 569,598,000 \$ 544,276,000

13. Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, patient receivables, prepaid expenses and other current assets, accounts payable, accrued salaries, wages and benefits, other accrued expenses, and advances from third-party payors approximate fair value, given the short-term nature of these financial instruments and/or their methods of valuation. The following methods and assumptions were used by the Group in estimating the fair value of other financial instruments:

Investments and Assets Whose Use Is Limited

Fair values are based on quoted market prices, if available, or estimated using quoted market prices for similar securities.

Notes to Consolidated Financial Statements (continued)

13. Fair Value of Financial Instruments (continued)

Pledges Receivable

The Group estimates that the carrying value of pledges receivable approximates fair value, given the discount rates applied.

Long-Term Debt

Fair values of the Group's fixed rate long-term debt are established using discounted cash flow analyses, based on the Group's current incremental borrowing rates for similar types of borrowing arrangements. The carrying amount of the Group's variable rate long-term debt approximates fair value. The estimated fair value of all long-term debt at June 30, 2013 and 2012, was approximately \$442,890,000 and \$460,940,000, respectively.

14. Temporarily Restricted Net Assets

At June 30, 2013 and 2012, temporarily restricted net assets are restricted for use, as follows:

	2013	2012
Hospital capital additions	\$ 12,215,000	\$ 14,003,000
Hospital operating programs	7,652,000	4,890,000
	\$ 19,867,000	\$ 18,893,000

15. Subsequent Events

The Group has evaluated the impact of subsequent events through October 18, 2013, representing the date at which the consolidated financial statements were issued.

Supplementary Information

Supplementary Consolidating Balance Sheet

June 30, 2013

	Anne	Anne Arundel Medical	Anne Arundel	Anne Arundel Real Estate Holding	Cottage	AAHS		Anne Arundel Medical	Consolid Eliminati	· ·	
	Arundel Health System, Inc.	Center, Inc. and Subsidiaries	Health Care Enterprises, Inc.	Company, Inc. and Subsidiaries	Insurance Company, Ltd.	Research Institute, Inc.	Physician Enterprise, LLC	Center Foundation, Inc.	Cottage Insurance Company, Ltd.	Other Subsidiaries	Consolidated
Assets	bystem, me.	Subsidiaries	IIIC.	Subsidiaries	Ltu.	IIIC.	LLC	IIIC.	Company, Etu.	Subsidiaries	Consolidated
Current assets:											
Cash and cash equivalents	\$ 473,000	\$ 35,620,000	\$ 6,000 5	1.398.000 \$	- :	\$ 13,000 S	201.000	\$ 4.517.000	s – s	_	\$ 42,228,000
Short-term investments	_	1,240,000	_	_	_		_	1,095,000		_	2,335,000
Current portion of assets whose use is limited	=-	14,826,000		_	2,730,000	_		_	_	-	17,556,000
Patient receivables, net	_	72,461,000	=.	-		_	5,351,000	-	-	=	77,812,000
Current portion of pledges receivable, net	-		=.	-	-	_		5,480,000	-	=	5,480,000
Inventories	-	8,204,000	112,000	-	-	_	=	-	-	=	8,316,000
Prepaid expenses and other current assets	-	52,209,000	1,379,000	1,164,000	30,000	5,000	=	6,000	(4,000,000)	(40,962,000) (1),(4)	9,831,000
Total current assets	473,000	184,560,000	1,497,000	2,562,000	2,760,000	18,000	5,552,000	11,098,000	(4,000,000)	(40,962,000)	163,558,000
Property and equipment	_	644,864,000	11,256,000	133,079,000	_	69,000	_	212,000	_	=	789,480,000
Less accumulated depreciation and amortization	_	(250,346,000)	(6,703,000)	(37,274,000)	_	(47,000)	_	(210,000)	_	_	(294,580,000)
Net property and equipment	=	394,518,000	4,553,000	95,805,000	=	22,000	=	2,000	=	=	494,900,000
Other assets:											
Investments	_	222,335,000	_	_	_	_	_	1,702,000	_	_	224.037.000
Investments in joint ventures	_	,	818,000	7,397,000	_	_	_	-,,	_	_	8,215,000
Pledges receivable, net	_	-	-	-	_	_	_	7.672.000	_	_	7,672,000
Assets whose use is limited	_	22,269,000	_	_	23,359,000	_	_	14,233,000	_	_	59,861,000
Deferred debt issue costs, net	=-	6,107,000		321,000	-	_		_	_	-	6,428,000
Beneficial interest in net assets of											
AAMC Foundation, Inc.	=	31,716,000	=	_	_	_	_	_	_	(31,716,000) (7)	=
Restricted collateral for interest rate											
swap contract	=	49,775,000	=	_	_	_	_	_	_	=	49,775,000
Investment in subsidiaries and other assets	403,400,000	17,413,000	_	_	9,413,000	_	1,224,000	332,000	_	(420,033,000) (1),(2),(4)	11,749,000
Total assets	\$ 403,873,000	\$ 928,693,000	\$ 6,868,000	\$ 106,085,000 \$	35,532,000	\$ 40,000 \$	6,776,000	\$ 35,039,000	\$ (4,000,000) \$	(492,711,000)	\$ 1,026,195,000

46 1303-1037905

Supplementary Consolidating Balance Sheet (continued)

June 30, 2013

		Anne Arundel	Anne	Anne Arundel Real Estate	G ::	AAHS		Anne Arundel	Consolidating and Eliminating Entries		
	Anne Medical Arundel Center,		Arundel Health Care	Holding Company, Inc.			Physician	Medical Center	Cottage	ng Entries	
	Health	Inc. and	Enterprises,	and	Company,	Institute,	Enterprise,	Foundation,	Insurance	Other	
	System, Inc.	Subsidiaries	Inc.	Subsidiaries	Ltd.	Inc.	LLC	Inc.	Company, Ltd.	Subsidiaries	Consolidated
Liabilities and net assets											
Current liabilities:											
Accounts payable	\$ - 5	20,060,000	\$ 8,311,000 \$	414,000 \$	4,067,000	\$ 4,201,000 \$	26,903,000	\$ 2,737,000	\$ (4,000,000) \$	(40,442,000) (1)	\$ 22,251,000
Accrued salaries, wages, and benefits	-	25,441,000	1,026,000	-	-	-	4,061,000	-	-	-	30,528,000
Other accrued expenses	-	17,565,000	13,000	1,056,000	3,316,000	-	_	586,000	-	-	22,536,000
Current portion of long-term debt and											
capital lease obligations	-	4,935,000	_	3,817,000	-	-	_	-	-	(520,000) (4)	8,232,000
Advances from third-party payors		21,453,000	_	-	-	_	_	_	-	-	21,453,000
Total current liabilities		89,454,000	9,350,000	5,287,000	7,383,000	4,201,000	30,964,000	3,323,000	(4,000,000)	(40,962,000)	105,000,000
Long-term debt and capital lease obligations, less current portion and unamortized											
original issue discount	-	330,744,000	-	86,968,000	=-	-	-	-	-	(5,198,000) (4)	412,514,000
Interest rate swap contract	-	53,002,000	-	-	=-	-	-	-	=-	-	53,002,000
Accrued pension liability	-	30,604,000	_	-	-	-	_	-	-	-	30,604,000
Other long-term liabilities		-	_	11,435,000	18,582,000	_	2,654,000	_	-	(11,435,000) (1)	21,236,000
Total liabilities		503,804,000	9,350,000	103,690,000	25,965,000	4,201,000	33,618,000	3,323,000	(4,000,000)	(57,595,000)	622,356,000
Net assets:											
Unrestricted	372,577,000	393,593,000	(2,482,000)	2,395,000	9,567,000	(4,161,000)	(26,842,000)	1,100,000	=	(373,204,000) (2),(7)	372,543,000
Temporarily restricted	19,867,000	19,867,000	_	-	_	_	_	19,867,000	-	(39,734,000) (2),(7)	19,867,000
Permanently restricted	11,429,000	11,429,000	-	-	-	_	-	10,749,000	-	(22,178,000) (2),(7)	11,429,000
Total net assets	403,873,000	424,889,000	(2,482,000)	2,395,000	9,567,000	(4,161,000)	(26,842,000)	31,716,000	=	(435,116,000)	403,839,000
Total liabilities and net assets	\$ 403,873,000	928,693,000	\$ 6,868,000 \$	106,085,000 \$	35,532,000	\$ 40,000 \$	6,776,000	\$ 35,039,000	\$ (4,000,000) \$	(492,711,000)	\$ 1,026,195,000

47 1303-1037905

Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses

Year Ended June 30, 2013

	Anne	Anne Arundel Medical	Anne Arundel	Anne Arundel Real Estate Holding	Cottage	AAHS		Anne Arundel Medical	Consolidat Eliminating	U	
	Arundel Health System, Inc.	Center, Inc. and Subsidiaries	Health Care Enterprises, Inc.	Company, Inc. and Subsidiaries	Insurance Company, Ltd.	Research Institute, Inc.	Physician Enterprise, LLC	Center Foundation, Inc.	Cottage Insurance Company, Ltd.	Other Subsidiaries	Consolidated
Operating revenue: Net patient service revenue Provision for bad debts	\$ - \$	508,509,000 (22,606,000)	\$ -	\$ – –	\$ - -	\$ - -	\$ 63,593,000 (3,957,000)	\$ – –	\$ - -	\$ – –	\$ 572,102,000 (26,563,000)
Net patient service revenue less provsion for bad debts	_	485,903,000	_	_	_	_	59,636,000	_	_	_	545,539,000
Other operating revenue	1,276,000	15,468,000	22,186,000	19,236,000	4,087,000	1,384,000	16,825,000	-	(4,332,000)	(49,247,000) (3),(6)	
Total operating revenue	1,276,000	501,371,000	22,186,000	19,236,000	4,087,000	1,384,000	76,461,000	_	(4,332,000)	(49,247,000)	- 572,422,000
Operating expenses:											
Salaries and wages	\$ - \$	186,518,000	\$ 15,052,000	\$ -	\$ -	\$ 1,175,000	\$ 43,248,000	\$ 861,000	\$ -	\$ (2,036,000) ⁽³⁾	\$ 244,818,000
Employee benefits	_	36,073,000	2,170,000	_	_	259,000	3,825,000	189,000	_	(449,000) (3)	42,067,000
Medical supplies and drugs	_	116,517,000	56,000	2,000	_	17,000	2,721,000	10,000	_	_	119,323,000
Purchased services	1,275,000	93,627,000	4,005,000	9,895,000	2,532,000	387,000	31,945,000	1,246,000	(4,332,000)	(46,620,000) ⁽³⁾	93,960,000
Professional fees	-	15,419,000	_	_	_	7,000	1,065,000	_	_	(55,000) (3)	16,436,000
Depreciation and amortization	_	29,963,000	1,240,000	4,554,000	_	10,000	_	1,000	_	_	35,768,000
Interest		15,973,000	_	1,340,000	_	-	-	_	-	(87,000) ⁽⁶⁾	17,226,000
Total operating expenses	1,275,000	494,090,000	22,523,000	15,791,000	2,532,000	1,855,000	82,804,000	2,307,000	(4,332,000)	(49,247,000)	569,598,000
Operating income (loss)	1,000	7,281,000	(337,000)	3,445,000	1,555,000	(471,000)	(6,343,000)	(2,307,000)		-	2,824,000
Other income (loss):											
Investment income, net	_	11,847,000	_	34,000	1,806,000	_	_	71,000	_	_	13,758,000
Income (Loss) from joint ventures and other, net	46,007,000	(1,669,000)	190,000	138,000	_	_	_	_	_	(46,007,000) (5)	(1,341,000)
Loss on extinguishment of debt	-	(3,561,000)	-	-	-	-	-	-	-	-	(3,561,000)
Change in unrealized gains (losses) on trading											
securities, net	_	7,911,000	-	_	(187,000)	-	_	73,000	_	_	7,797,000
Realized and unrealized losses on											
interest rate swap contracts, net		23,533,000		_	_				_		23,533,000
Total other income, net	46,007,000	38,061,000	190,000	172,000	1,619,000			144,000		(46,007,000)	40,186,000
Revenues and gains in excess of (less than) expenses	\$ 46,008,000 \$	45,342,000	\$ (147,000)	\$ 3,617,000	\$ 3,174,000	\$ (471,000)	\$ (6,343,000)	\$ (2,163,000)	\$ -	\$ (46,007,000)	\$ 43,010,000

48 1303-1037905

Anne Arundel Medical Center, Inc. and Subsidiaries

Supplementary Consolidating Balance Sheet

June 30, 2013

	Anne Arundel Medical Center, Inc.	Anne Arundel Health Care Services, Inc.	Anne Arundel General Treatment Services, Inc.	Consolidating and Eliminating Entries	Consolidated	
Assets	IIIC.	Ser vices, inc.	Ser vices, inc.	Littles	Consonauteu	
Current assets:						
Cash and cash equivalents	\$ 26,120,000	\$ 9,499,000	\$ 1,000	\$ -	\$ 35,620,000	
Short-term investments	1,240,000	_	_	_	1,240,000	
Current portion of assets whose use is limited	14,826,000	_	_	_	14,826,000	
Patient receivables, net	68,059,000	3,844,000	558,000	_	72,461,000	
Inventories	8,204,000	_	_	_	8,204,000	
Due from affiliates, net	45,003,000	32,147,000	335,000	$(32,482,000)^{(1)}$	45,003,000	
Prepaid expenses and other current assets	7,174,000	31,000	1,000	_	7,206,000	
Total current assets	170,626,000	45,521,000	895,000	(32,482,000)	184,560,000	
Property and equipment	610,202,000	28,774,000	5,888,000	_	644,864,000	
Less accumulated depreciation and amortization	(224,389,000)	(22,814,000)		_	(250,346,000)	
Net property and equipment	385,813,000	5,960,000	2,745,000	_	394,518,000	
Other assets:						
Investments	222,335,000	_	_	_	222,335,000	
Assets whose use is limited	22,269,000	_	_	_	22,269,000	
Deferred debt issue costs, net	6,107,000	_	_	_	6,107,000	
Beneficial interest in net assets of	2,221,000				0,201,000	
Anne Arundel Medical Center Foundation, Inc.	31,716,000	_	_	_	31,716,000	
Notes receivable from affiliate	5,198,000	_	_	_	5,198,000	
Restricted collateral for interest rate swap	, ,				, , , , , , , , , , , , , , , , , , , ,	
contract	49,775,000	_	_	_	49,775,000	
Investments in subsidiaries and other assets, net	65,580,000	28,000	_	$(53,393,000)^{(2)}$	12,215,000	
Total assets	\$ 959,419,000	\$ 51,509,000	\$ 3,640,000	\$ (85,875,000)	\$ 928,693,000	

Anne Arundel Medical Center, Inc. and Subsidiaries

Supplementary Consolidating Balance Sheet (continued)

June 30, 2013

	Anne Arundel Medical Center, Inc.		Anne Arundel Health Care Services, Inc.		Anne Arundel General Treatment Services, Inc.		Consolidating and Eliminating Entries		Consolidated	
Liabilities and net assets				ĺ		· ·				
Current liabilities:										
Accounts payable	\$	18,304,000	\$	1,735,000	\$	21,000	\$	_	\$	20,060,000
Accrued salaries, wages, and benefits		25,441,000		_		_		_		25,441,000
Other accrued expenses		17,565,000		_		_		_		17,565,000
Current portion of long-term debt and capital										
lease obligations		4,935,000		_		_		_		4,935,000
Intercompany payables		32,482,000		_		_		$(32,482,000)^{(1)}$		_
Advances from third-party payors		21,453,000		_		_		_		21,453,000
Total current liabilities		120,180,000		1,735,000		21,000		(32,482,000)		89,454,000
Long-term debt and capital lease obligations,										
less current portion and unamortized original		220 744 000								220 744 000
issue discount		330,744,000		_		-		_		330,744,000
Interest rate swap contract		53,002,000		_		_		_		53,002,000
Accrued pension liability		30,604,000		1 725 000		21.000		- (22, 492, 999)		30,604,000
Total liabilities		534,530,000		1,735,000		21,000		(32,482,000)		503,804,000
Net assets:										
Unrestricted		393,593,000		49,774,000		3,619,000		$(53,393,000)^{(2)}$		393,593,000
Temporarily restricted		19,867,000		_		_		_		19,867,000
Permanently restricted		11,429,000		_		_		_		11,429,000
Total net assets		424,889,000		49,774,000		3,619,000		(53,393,000)		424,889,000
Total liabilities and net assets	\$	959,419,000	\$	51,509,000	\$	3,640,000	\$	(85,875,000)	\$	928,693,000

Anne Arundel Medical Center, Inc. and Subsidiaries

Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses

Year Ended June 30, 2013

	Anne Arundel Medical Center,	Anne Arundel Health Care	Anne Arundel General Treatment	8	
	Inc.	Services, Inc.	Services, Inc.	Entries	Consolidated
Operating revenue:					
Net patient service revenue	\$ 471,230,000	\$ 32,041,000	\$ 5,238,000	\$ -	\$ 508,509,000
Provision for bad debts	(19,751,000)	(2,571,000)	(284,000)	_	(22,606,000)
Net patient service revenue less provsion for bad debts	451,479,000	29,470,000	4,954,000	_	485,903,000
Other operating revenue	26,036,000	60,000	81,000	$(10,709,000)^{(3)}$	15,468,000
Total operating revenue	477,515,000	29,530,000	5,035,000	(10,709,000)	501,371,000
Operating expenses:					
Salaries and wages	186,518,000	5,370,000	3,028,000	$(8,398,000)^{(3)}$	186,518,000
Employee benefits	36,074,000	1,181,000	666,000	$(1,848,000)^{(3)}$	36,073,000
Medical supplies and drugs	115,094,000	1,195,000	283,000	$(55,000)^{(3)}$	116,517,000
Purchased services	85,749,000	7,692,000	594,000	$(408,000)^{(3)}$	93,627,000
Professional fees	8,621,000	6,751,000	47,000	_	15,419,000
Depreciation and amortization	28,371,000	1,441,000	151,000	_	29,963,000
Interest	15,973,000	_	_	_	15,973,000
Total operating expenses	476,400,000	23,630,000	4,769,000	(10,709,000)	494,090,000
Operating income	1,115,000	5,900,000	266,000	_	7,281,000
Other income (loss):					
Investment income, net	11,847,000	_	_	_	11,847,000
Income (loss) from joint venture and other, net	4,497,000	_	_	$(6,166,000)^{(5)}$	(1,669,000)
Loss on extinguishment of debt	(3,561,000)	_	_	_	(3,561,000)
Change in unrealized gains on trading securities, net	7,911,000	_	_	_	7,911,000
Realized and unrealized losses on					
interest rate swap contracts, net	23,533,000	_	_	_	23,533,000
Total other income (loss), net	44,227,000	-	_	(6,166,000)	38,061,000
Revenues and gains in excess of (less than) expenses	\$ 45,342,000	\$ 5,900,000	\$ 266,000	\$ (6,166,000)	\$ 45,342,000

51

Supplementary Description of Consolidating and Eliminating Entries

- 1. To eliminate intercompany payables/receivables.
- 2. To eliminate investment in subsidiaries and related net asset accounts.
- 3. To eliminate intercompany income/expense generated from management fees, staffing contracts, captive insurance premiums, and operating leases.
- 4. To eliminate intercompany notes.
- 5. To eliminate income of wholly owned subsidiaries.
- 6. To eliminate intercompany revenue/expense for interest and other miscellaneous transactions.
- 7. To eliminate the Hospital's beneficial interest in Anne Arundel Medical Center Foundation, Inc.

Ernst & Young LLP

Assurance | Tax | Transactions | Advisory

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services.
Worldwide, our 167,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

For more information, please visit www.ey.com

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity.

Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. This Report has been prepared by Ernst & Young LLP, a client serving member firm located in the United States.

